IRF1 and cancer: Moreover, we found IRF1 to be a dominant inducer of CD274 expression in all three cancer types we studied, which is consistent with IFN-γ being a dominant cytokine driving PD-L1 expression in tumors41, because it primarily signals through the canonical type II interferon pathway, activating the TF IRF142–44.